

# David S Baldwin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8781005/david-s-baldwin-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203  
papers

6,472  
citations

43  
h-index

75  
g-index

222  
ext. papers

7,662  
ext. citations

4.5  
avg, IF

6.02  
L-index

#	Paper	IF	Citations
203	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. <i>World Journal of Biological Psychiatry</i> , <b>2008</b> , 9, 248-312	3.8	496
202	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2005</b> , 19, 567-96	4.6	449
201	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 403-39	4.6	387
200	Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2011</b> , 342, d1199	5.9	190
199	Generalised anxiety disorder. <i>Lancet, The</i> , <b>2006</b> , 368, 2156-66	4.0	181
198	Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. <i>British Journal of Psychiatry</i> , <b>1999</b> , 175, 120-6	5.4	162
197	What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1428-34	4.6	153
196	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , <b>2017</b> , 18, 162-214	3.8	143
195	Transcranial direct current stimulation (tDCS) in the treatment of depression: Systematic review and meta-analysis of efficacy and tolerability. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2015</b> , 57, 46-62	9	131
194	Benzodiazepines: risks and benefits. A reconsideration. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 967-71	4.6	130
193	Escitalopram therapy for major depression and anxiety disorders. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 1583-92	2.9	114
192	A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 482-91	1.2	111
191	The economic consequences of social phobia. <i>Journal of Affective Disorders</i> , <b>2002</b> , 68, 221-33	6.6	103
190	British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>Journal of Psychopharmacology</i> , <b>2017</b> , 31, 519-552	4.6	102
189	Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. <i>British Journal of Psychiatry</i> , <b>2006</b> , 189, 264-72	5.4	99
188	Evidence-based pharmacological treatment of generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2011</b> , 14, 697-710	5.8	97
187	Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1741-6	4.6	95

186	Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , <b>2016</b> , 17, 321-65	3.8	93
185	Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 204-10	4.6	90
184	Evidence-based pharmacotherapy of Generalized Anxiety Disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2005</b> , 8, 293-302	5.8	87
183	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. <i>Brain, Behavior, and Immunity</i> , <b>2017</b> , 62, 212-218	16.6	86
182	The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 242-52	4.6	81
181	The SSRIs: advantages, disadvantages and differences. <i>Journal of Psychopharmacology</i> , <b>1995</b> , 9, 163-78	4.6	79
180	Discontinuation symptoms in depression and anxiety disorders. <i>International Journal of Neuropsychopharmacology</i> , <b>2007</b> , 10, 73-84	5.8	75
179	Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , <b>2019</b> , 79, 24-38	16.6	71
178	Sexual dysfunction associated with antidepressant drugs. <i>Expert Opinion on Drug Safety</i> , <b>2004</b> , 3, 457-70	4.1	70
177	Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. <i>European Neuropsychopharmacology</i> , <b>2008</b> , 18, 422-30	1.2	69
176	A neuroimmunological perspective on anxiety disorders. <i>Human Psychopharmacology</i> , <b>2012</b> , 27, 6-14	2.3	68
175	A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , <b>2006</b> , 21, 159-69	2.2	68
174	The generalized anxiety spectrum: prevalence, onset, course and outcome. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2009</b> , 259, 37-45	5.1	66
173	The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. <i>World Psychiatry</i> , <b>2018</b> , 17, 3-11	14.4	65
172	Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. <i>Human Psychopharmacology</i> , <b>2010</b> , 25, 17-29	2.3	58
171	Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. <i>Psychopharmacology</i> , <b>2004</b> , 176, 466-70	4.7	54
170	Role of dopamine in schizophrenia and Parkinson's disease. <i>British Journal of Nursing</i> , <b>1998</b> , 7, 832-4, 836, 838-41	0.7	52
169	Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 1717-24	2.5	49

168	Research in anxiety disorders: from the bench to the bedside. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 381-90	1.2	48
167	Placebo-controlled studies in depression: necessary, ethical and feasible. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2003</b> , 253, 22-8	5.1	48
166	Pregabalin for the treatment of generalized anxiety disorder: an update. <i>Neuropsychiatric Disease and Treatment</i> , <b>2013</b> , 9, 883-92	3.1	47
165	Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. <i>Journal of Psychopharmacology</i> , <b>2006</b> , 20, 91-6	4.6	47
164	A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. <i>Journal of Affective Disorders</i> , <b>2016</b> , 206, 140-150	6.6	45
163	A systematic review of the predictors of health service utilisation by adults with mental disorders in the UK. <i>BMJ Open</i> , <b>2015</b> , 5, e007575	3	44
162	Inhalation of 7.5% carbon dioxide increases threat processing in humans. <i>Neuropsychopharmacology</i> , <b>2011</b> , 36, 1557-62	8.7	43
161	An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. <i>World Journal of Biological Psychiatry</i> , <b>2012</b> , 13, 510-6	3.8	43
160	How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. <i>Human Psychopharmacology</i> , <b>2009</b> , 24, 269-75	2.3	39
159	Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. <i>Drug Safety</i> , <b>2016</b> , 39, 627-45	5.1	38
158	Investigation of cortisol levels in patients with anxiety disorders: a structured review. <i>Current Topics in Behavioral Neurosciences</i> , <b>2014</b> , 18, 191-216	3.4	37
157	Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 778-83	4.6	36
156	Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 1047-60	4.6	35
155	Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , <b>2012</b> , 27, 197-207	2.2	35
154	Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function. <i>Psychopharmacology</i> , <b>2012</b> , 223, 67-73	4.7	34
153	Effects of antidepressant drugs on sexual function. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>1997</b> , 1, 47-58	2.4	34
152	Impact of Antidepressant Drugs on Sexual Function and Satisfaction. <i>CNS Drugs</i> , <b>2015</b> , 29, 905-13	6.7	33
151	Role of pregabalin in the treatment of generalized anxiety disorder. <i>Neuropsychiatric Disease and Treatment</i> , <b>2007</b> , 3, 185-91	3.1	31

150	Effects of age and gender on elderly suicide rates in Catholic and Orthodox countries: an inadvertent neglect?. <i>International Journal of Geriatric Psychiatry</i> , <b>2000</b> , 15, 904-10	3.9	30
149	Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder. <i>Translational Psychiatry</i> , <b>2018</b> , 8, 75	8.6	29
148	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2011</b> , 261 Suppl 3, 207-45	5.1	29
147	Clinically relevant drug interactions in anxiety disorders. <i>Human Psychopharmacology</i> , <b>2012</b> , 27, 239-53	2.3	28
146	Preferential Consolidation of Emotional Memory During Sleep: A Meta-Analysis. <i>Frontiers in Psychology</i> , <b>2019</b> , 10, 1014	3.4	27
145	Escitalopram in the treatment of generalized anxiety disorder. <i>Expert Review of Neurotherapeutics</i> , <b>2005</b> , 5, 443-9	4.3	27
144	Pharmacology for sleep disturbance in PTSD. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 156-63	2.3	25
143	Lithium and sexual dysfunction: an under-researched area. <i>Human Psychopharmacology</i> , <b>2015</b> , 30, 66-9	2.3	24
142	A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. <i>Current Psychiatry Reports</i> , <b>2010</b> , 12, 471-7	9.1	24
141	Symptoms of fatigue and sleepiness in major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67 Suppl 6, 9-15	4.6	24
140	Altered executive control network resting-state connectivity in social anxiety disorder. <i>World Journal of Biological Psychiatry</i> , <b>2016</b> , 17, 47-57	3.8	23
139	Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder. <i>Brain, Behavior, and Immunity</i> , <b>2019</b> , 81, 105-110	16.6	23
138	Superiority of escitalopram to paroxetine in the treatment of depression. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 229-37	1.2	22
137	Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. <i>Human Psychopharmacology</i> , <b>2008</b> , 23, 527-32	2.3	22
136	Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. <i>Journal of Psychopharmacology</i> , <b>1998</b> , 12, 323-9	4.6	21
135	The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. <i>Journal of Anxiety Disorders</i> , <b>2014</b> , 28, 741-6	10.9	20
134	Pharmacological treatment of generalized anxiety disorder. <i>Current Topics in Behavioral Neurosciences</i> , <b>2010</b> , 2, 453-67	3.4	20
133	Treatment of Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , <b>2007</b> , 12, 28-35	1.8	20

132	Off-label prescribing by psychiatrists. <i>Psychiatric Bulletin</i> , <b>2000</b> , 24, 415-417		20
131	Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. <i>Depression Research and Treatment</i> , <b>2013</b> , 2013, 256841	3.8	19
130	The Asian Cultural Identity Schedule: an investigation of culture and deliberate self-harm. <i>International Journal of Methods in Psychiatric Research</i> , <b>1999</b> , 8, 212-218	4.3	18
129	Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets. <i>CNS Drugs</i> , <b>2017</b> , 31, 307-317	6.7	17
128	Evaluating psychological interventions in a novel experimental human model of anxiety. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 63, 117-22	5.2	17
127	Daytime intrusive thoughts and subjective insomnia symptoms. <i>Psychiatry Research</i> , <b>2015</b> , 229, 1038-42	9.9	17
126	The Effect of Prefrontal Transcranial Direct Current Stimulation on Attention Network Function in Healthy Volunteers. <i>Neuromodulation</i> , <b>2018</b> , 21, 355-361	3.1	17
125	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2012</b> , 262, 13-22	5.1	17
124	Manifesto for a European anxiety disorders research network. <i>European Neuropsychopharmacology</i> , <b>2010</b> , 20, 426-32	1.2	17
123	Covid-19: doctors must take control of their wellbeing. <i>BMJ, The</i> , <b>2020</b> , 369, m1725	5.9	16
122	Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. <i>Health Technology Assessment</i> , <b>2014</b> , 18, 1-59, v-vi	4.4	16
121	Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review. <i>Acta Neuropsychiatrica</i> , <b>2014</b> , 26, 125-9	3.9	16
120	Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2006</b> , 10 Suppl 2, 12-5	2.4	16
119	Psychotropic Drugs and Sexual Dysfunction. <i>International Review of Psychiatry</i> , <b>1995</b> , 7, 261-273	3.6	16
118	Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder?. <i>International Clinical Psychopharmacology</i> , <b>2016</b> , 31, 347-52 <sup>2</sup>	2.2	16
117	The separation of adult separation anxiety disorder. <i>CNS Spectrums</i> , <b>2016</b> , 21, 289-94	1.8	16
116	Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 1062-9	1.2	15
115	Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. <i>Human Psychopharmacology</i> , <b>2017</b> , 32, e2628 <sup>3</sup>	2.3	15

114	Room for improvement in the pharmacological treatment of anxiety disorders. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 3482-91	3.3	15
113	Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. <i>Annals of Pharmacotherapy</i> , <b>2006</b> , 40, 1752-8	2.9	15
112	Can we distinguish anxiety from depression?. <i>Psychopharmacology Bulletin</i> , <b>2002</b> , 36 Suppl 2, 158-65	0.9	15
111	Oxytocin receptor and G-protein polymorphisms in patients with depression and separation anxiety. <i>Journal of Affective Disorders</i> , <b>2017</b> , 218, 365-373	6.6	14
110	Effects of repeated attachment security priming in outpatients with primary depressive disorders. <i>Journal of Affective Disorders</i> , <b>2018</b> , 234, 201-206	6.6	14
109	Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 137-42 <sup>1.2</sup>	1.2	14
108	A factor analysis of posttraumatic stress disorder symptoms using data pooled from two venlafaxine extended-release clinical trials. <i>Brain and Behavior</i> , <b>2013</b> , 3, 738-46	3.4	14
107	Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. <i>Journal of Psychopharmacology</i> , <b>2008</b> , 22, 55-63	4.6	13
106	Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder. <i>International Clinical Psychopharmacology</i> , <b>2018</b> , 33, 334-348	2.2	13
105	Health literacy and the pharmacological treatment of anxiety disorders: a systematic review. <i>Human Psychopharmacology</i> , <b>2014</b> , 29, 211-5	2.3	12
104	Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?. <i>CNS Spectrums</i> , <b>2006</b> , 11, 34-9	1.8	12
103	Manifesto for an international digital mental health network <b>2019</b> , 2, 14-24		11
102	Pharmacological treatment of panic disorder. <i>Modern Problems of Pharmacopsychiatry</i> , <b>2013</b> , 29, 128-43		11
101	The overlap of obsessive-compulsive disorder and social phobia and its treatment. <i>CNS Spectrums</i> , <b>2008</b> , 13, 47-53	1.8	11
100	Unmet needs in the pharmacological management of depression. <i>Human Psychopharmacology</i> , <b>2001</b> , 16, S93-S99	2.3	11
99	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. <i>Journal of Psychopharmacology</i> , <b>2001</b> , 15, 161-5	4.6	11
98	Identity in recovery from problematic alcohol use: A qualitative study of online mutual aid. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 174, 17-22	4.9	10
97	Structured review of the use of the Arizona sexual experiences scale in clinical settings. <i>Human Psychopharmacology</i> , <b>2020</b> , 35, e2730	2.3	10

96	Cancer, Benign Gynecology, and Sexual Function--Issues and Answers. <i>Journal of Sexual Medicine</i> , <b>2016</b> , 13, 519-37	1.1	10
95	Early effects of duloxetine on emotion recognition in healthy volunteers. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 634-41	4.6	10
94	Clinical experience with paroxetine in social anxiety disorder. <i>International Clinical Psychopharmacology</i> , <b>2000</b> , 15 Suppl 1, S19-24	2.2	10
93	The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. <i>World Psychiatry</i> , <b>2021</b> , 20, 336-356	14.4	10
92	Utility of the Health of the Nation Outcome Scales (HoNOS) in Predicting Mental Health Service Costs for Patients with Common Mental Health Problems: Historical Cohort Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0167103	3.7	9
91	Systematic review of blood transcriptome profiling in neuropsychiatric disorders: guidelines for biomarker discovery. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 373-81	2.3	9
90	Anxiety symptom severity and functional recovery or relapse. <i>Annals of Clinical Psychiatry</i> , <b>2009</b> , 21, 81-84	1.4	9
89	Poor monitoring of physical health in patients referred to a mood disorders service. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2015</b> , 5, 22-5	4.9	8
88	Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 966	11.9	8
87	Escitalopram: efficacy and tolerability in the treatment of depression. <i>British Journal of Hospital Medicine</i> , <b>2002</b> , 63, 668-71		8
86	Genetic mechanisms of electroconvulsive therapy response in depression. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 247-51	2.3	8
85	Antidepressants, withdrawal, and addiction; where are we now?. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 655-659	4.6	7
84	Efficacy of vortioxetine on the physical symptoms of major depressive disorder. <i>Journal of Psychopharmacology</i> , <b>2018</b> , 32, 1086-1097	4.6	7
83	Dysthymia. <i>CNS Drugs</i> , <b>1995</b> , 4, 422-431	6.7	7
82	Prevalence, clinical correlates and IQ of suicidal ideation in drug naïve Chinese Han patients with major depressive disorder. <i>Journal of Affective Disorders</i> , <b>2019</b> , 248, 59-64	6.6	7
81	Developing a European research network to address unmet needs in anxiety disorders. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2013</b> , 37, 2312-7	9	6
80	Should benzodiazepines still have a role in treating patients with anxiety disorders?. <i>Human Psychopharmacology</i> , <b>2012</b> , 27, 237-8	2.3	6
79	The pharmacologic treatment of patients with generalized anxiety disorder: where are we now and where are we going?. <i>CNS Spectrums</i> , <b>2009</b> , 14, 5-12	1.8	6



78	The future of antidepressant pharmacotherapy. <i>World Psychiatry</i> , <b>2003</b> , 2, 3-8	14.4	6
77	Yogic Breathing Instruction in Patients with Treatment-Resistant Generalized Anxiety Disorder: Pilot Study. <i>International Journal of Yoga</i> , <b>2019</b> , 12, 78-83	1.6	6
76	Vortioxetine in the treatment of major depressive disorder. <i>Future Neurology</i> , <b>2015</b> , 10, 79-89	1.5	5
75	A neurobiological framework of separation anxiety and related phenotypes. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 33, 45-57	1.2	5
74	Attentional biases in patients with alcohol dependence: influence of coexisting psychopathology. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 395-401	2.3	5
73	Pharmacological treatment of social phobia. <i>Psychiatry (Abingdon, England)</i> , <b>2007</b> , 6, 217-223		5
72	Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder. <i>Expert Review of Neurotherapeutics</i> , <b>2002</b> , 2, 717-24	4.3	5
71	Obsessive-compulsive symptoms and the Covid-19 pandemic: A rapid scoping review. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2021</b> ,	9	5
70	Sense and Sensibility When Prescribing 'Off-Label' to Psychiatric Patients. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 3276-9	3.3	5
69	Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk?. <i>CNS Drugs</i> , <b>2020</b> , 34, 163-169	6.7	5
68	Cross-sectional associations of depressive symptom severity and functioning with health service use by older people in low-and-middle income countries. <i>International Journal of Environmental Research and Public Health</i> , <b>2015</b> , 12, 3774-92	4.6	4
67	Why we need more research into the placebo response in psychiatry. <i>Psychological Medicine</i> , <b>2020</b> , 50, 2317-2323	6.9	4
66	The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2021</b> , 125, 296-313	9	4
65	Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively. <i>CNS Drugs</i> , <b>2021</b> , 35, 703-716	6.7	4
64	Altruism, personal benefit, and anxieties: a phenomenological study of healthy volunteers' experiences in a placebo-controlled trial of duloxetine. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 332-40	2.3	3
63	Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study. <i>International Clinical Psychopharmacology</i> , <b>2014</b> , 29, 339-43	2.2	3
62	Psychiatry should not become hostage to placebo: an alternative interpretation of antidepressant-placebo differences in the treatment response in depression. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 782-6	1.2	3
61	Quality of case reports of adverse drug reactions with psychotropic drugs: a 25-year review. <i>Human Psychopharmacology</i> , <b>2013</b> , 28, 413-20	2.3	3

60	A critical review of the definition of 'wellbeing' for doctors and their patients in a post Covid-19 era. <i>International Journal of Social Psychiatry</i> , <b>2021</b> , 67, 984-991	8.5	3
59	Tapering of SSRI treatment to mitigate withdrawal symptoms. <i>Lancet Psychiatry</i> , <b>2019</b> , 6, 560-561	23.3	2
58	Does previous experience of antidepressants form the expectations necessary for a placebo response?. <i>British Journal of Psychiatry</i> , <b>2015</b> , 207, 561	5.4	2
57	Overcoming barriers in the pharmacological treatment of anxiety disorders. <i>Neuropsychiatry</i> , <b>2013</b> , 3, 33-44	1.8	2
56	Neurotic, stress-related and somatoform disorders <b>2010</b> , 453-491		2
55	Chapter 5.2 How effective are current drug treatments for anxiety disorders, and how could they be improved?. <i>Handbook of Behavioral Neuroscience</i> , <b>2008</b> , 395-411	0.7	2
54	Development and evaluation of psychotropic drugs. <i>Psychiatry (Abingdon, England)</i> , <b>2007</b> , 6, 279-283		2
53	The importance of long-term tolerability in achieving recovery. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2006</b> , 10 Suppl 1, 31-7	2.4	2
52	Pharmacological provocation and prevention of suicidal behaviour. <i>International Review of Psychiatry</i> , <b>2000</b> , 12, 54-61	3.6	2
51	Overcoming challenges in the management of schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>1999</b> , 3, 11-5	2.4	2
50	Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders: exploratory study. <i>International Clinical Psychopharmacology</i> , <b>2021</b> , 36, 126-132	2.2	2
49	Ruminations and their correlates in depressive episodes: Between-group comparison in patients with unipolar or bipolar depression and healthy controls. <i>Journal of Affective Disorders</i> , <b>2021</b> , 280, 1-6	6.6	2
48	Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2021</b> , 11, 20451253211002320	4.9	2
47	Brain Functional Connectivity Correlates of Response in the 7.5% CO2 Inhalational Model of Generalized Anxiety Disorder: A Pilot Study. <i>International Journal of Neuropsychopharmacology</i> , <b>2020</b> , 23, 268-273	5.8	1
46	A personal account of reducing and stopping antidepressant treatment. <i>International Clinical Psychopharmacology</i> , <b>2020</b> , 35, 194-200	2.2	1
45	Pharmacological Treatment of Anxiety Disorders <b>2014</b> , 865-882		1
44	Benzodiazepines: Risks and Benefits. A Reconsideration. <i>Focus (American Psychiatric Publishing)</i> , <b>2014</b> , 12, 229-234	1.1	1
43	Evidence-based pharmacotherapy of generalized anxiety disorder 110-127		1

42	Antidepressants for insomnia. <i>The Cochrane Library</i> , <b>2013</b> ,	5.2	1
41	Agomelatine improves symptoms of generalised anxiety disorder. <i>Evidence-Based Mental Health</i> , <b>2009</b> , 12, 54	11.1	1
40	Short-term treatment with hypnotic drugs for insomnia: going beyond the evidence. <i>Journal of Psychopharmacology</i> , <b>2005</b> , 19, 134-5	4.6	1
39	Antipsychotic drugs for non-psychotic patients: Results of a questionnaire survey of prescribing practices among Wessex psychiatrists. <i>Psychiatric Bulletin</i> , <b>1999</b> , 23, 416-418		1
38	Patient experience of lasting negative effects of psychological interventions for anxiety and depression in secondary mental health care services: a national cross-sectional study. <i>BMC Psychiatry</i> , <b>2021</b> , 21, 578	4.2	1
37	Safety and Tolerability of Antidepressants <b>2016</b> , 149-166		1
36	What is mental wellbeing?. <i>BJPsych Open</i> , <b>2021</b> , 7, S236-S236	5	1
35	Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?: A Case Series Using Phenelzine. <i>Journal of Clinical Psychopharmacology</i> , <b>2021</b> , 41, 461-464	1.7	1
34	Can cognitive behaviour therapy beneficially influence arousal mechanisms in psychosis?. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 64-9	2.3	1
33	A personal account of depressive illness and its antidepressant treatment. <i>International Clinical Psychopharmacology</i> , <b>2019</b> , 34, 286-290	2.2	1
32	Feasibility and acceptability of transcranial stimulation in obsessive-compulsive symptoms (FEATSOCS): study protocol for a randomised controlled trial of transcranial direct current stimulation (tDCS) in obsessive-compulsive disorder (OCD). <i>Pilot and Feasibility Studies</i> , <b>2021</b> , 7, 213	1.9	1
31	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 784370	5	0
30	Course and outcome of patients with alcohol use disorders following an alcohol intervention during hospital attendance: mixed method study. <i>BJPsych Open</i> , <b>2020</b> , 7, e6	5	0
29	The validity of the state-trait anxiety inventory and the brief scale for anxiety in an inpatient sample with alcohol use disorder. <i>Addiction</i> , <b>2021</b> , 116, 3055-3068	4.6	0
28	The effect of attachment security priming and oxytocin on physiological responses to trauma films and subsequent intrusions. <i>Behaviour Research and Therapy</i> , <b>2021</b> , 141, 103845	5.2	0
27	Mental wellbeing in doctors: the measure matters! development of a core outcome set for measuring wellbeing in doctors. <i>BJPsych Open</i> , <b>2021</b> , 7, S235-S236	5	0
26	Hair cortisol concentration in anxiety disorders: exploration of relationships with symptom severity and inflammatory markers. <i>Acta Neuropsychiatrica</i> , <b>2021</b> , 33, 104-110	3.9	0
25	Diverse predictors of treatment response to active medication and placebo in gambling disorder. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 144, 96-101	5.2	0

24 Drugs to Treat Anxiety and Insomnia **2020**, 268-289

23 Experimental Medicine Models in Generalized Anxiety Disorder and Social Anxiety Disorder. *Handbook of Behavioral Neuroscience*, **2019**, 29, 363-374 0.7

22 Recurrent brief depression **2014**, 100-113

21 Agomelatine in the treatment of mood and anxiety disorders. *British Journal of Hospital Medicine (London, England: 2005)*, **2010**, 71, 153-6 0.8

20 Introduction to Neuropsychopharmacology By Leslie L. Iversen, Susan D. Iversen, Floyd E. Bloom and Robert H. Roth Oxford University Press. 2009. £30.00 (pb). 558pp. ISBN: 9780195380538. *British Journal of Psychiatry*, **2010**, 196, 499-500 5.4

19 Suicide by veterinary surgeons. *Veterinary Record*, **2008**, 162, 355-356 0.9

18 Treatment of generalised anxiety and somatoform disorders 525-541

17 Depression and Personality: Conceptual and Clinical Challenges. Edited by Michael Rosenbluth, Sidney H. Kennedy & R. Michael Bagby. American Psychiatric Publishing. 2005. 338 pp. US\$39.95 (pb). ISBN 1585621544. *British Journal of Psychiatry*, **2007**, 190, 541-542 5.4

16 Clinical evaluation of psychotropic drugs. *Psychiatry (Abingdon, England)*, **2004**, 3, 14-17

15 Anxiety disorders: does one treatment fit all?. *International Journal of Psychiatry in Clinical Practice*, **2004**, 8 Suppl 1, 31-5 2.4

14 Discharging psychiatric patients from hospital. *Psychiatric Bulletin*, **2002**, 26, 436-436

13 Off-label prescribing. *Psychiatric Bulletin*, **2002**, 26, 394-394

12 Psychotropic Drug Directory 2003/04. The Professionals' Pocket Handbook & Aide Memoire. Stephen Bazire. Salisbury: Fivepin Publishing, 2003, £24.99 pb, 416 pp, ISBN: 0 95 448839 01. *Psychiatric Bulletin*, **2005**, 29, 239-239

11 SSRIs in the Treatment of Generalized Anxiety Disorder **2001**, 193-209

10 More scrutiny required: An audit of the distribution of The Royal College of Psychiatrists' Help is at Hand leaflet on social phobia. *International Journal of Health Promotion and Education*, **1999**, 37, 19-21 0.8

9 CURRENT VIEWS ON THE ETIOLOGY AND TREATMENT OF HYPERTENSION. *Journal of the American Geriatrics Society*, **1964**, 12, 239-44 5.6

8 Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study. *CNS Spectrums*, **2021**, 1-7 1.8

7 Capacity for cortical excitation is reduced in psychotic disorders: An investigation of the TMS-EMG cortical silent period.. *Schizophrenia Research*, **2021**, 240, 73-77 3.6

6 Pharmacological Treatment of Generalized Anxiety Disorder (GAD) **2020**, 297-318

5 Authors' Reply to Alain Brillon's Comment on "Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence". *Drug Safety*, **2016**, 39, 1153-1154

4 Quality of English inpatient mental health services for people with anxiety or depressive disorders: Findings and recommendations from the core audit of the National Clinical Audit of Anxiety and Depression. *Comprehensive Psychiatry*, **2021**, 104, 152212 7.3

3 What medical students think about measurement of their well-being: cross-sectional survey and qualitative interviews.. *BMJ Open*, **2022**, 12, e056749 3

2 Authors' Reply to Ulrich: Comment on 'Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively'. *CNS Drugs*, **2021**, 36, 103 6.7

1 Relationship of behavioral inhibition to separation anxiety in a sample (N=1377) of adult individuals with mood and anxiety disorders.. *Comprehensive Psychiatry*, **2022**, 116, 152326 7.3